tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AKRO Stock Latest News

Akero Therapeutics announces first patient dosed in Phase 3 SYNCHRONY study
The FlyAkero Therapeutics announces first patient dosed in Phase 3 SYNCHRONY study
11d ago
AKRO
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
PremiumPress Releases
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
11d ago
AKRO
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
PremiumPress Releases
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22d ago
AKRO
3 Best Stocks to Buy Now, 8/12/2024, According to Top Analysts 
PremiumMarket News
3 Best Stocks to Buy Now, 8/12/2024, According to Top Analysts 
1M ago
COP
PGY
Akero Therapeutics (AKRO) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Akero Therapeutics (AKRO) Q2 Earnings Cheat Sheet
1M ago
AKRO
Akero Therapeutics sees cash runway into 2H27
PremiumThe FlyAkero Therapeutics sees cash runway into 2H27
1M ago
AKRO
Akero Therapeutics reports Q2 EPS (81c), consensus (90c)
Premium
The Fly
Akero Therapeutics reports Q2 EPS (81c), consensus (90c)
1M ago
AKRO
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Premium
Press Releases
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
1M ago
AKRO
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
PremiumMarket News
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
3M ago
AKRO
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
PremiumPress Releases
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
3M ago
AKRO
Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial
PremiumThe Fly
Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial
3M ago
AKRO
Akero Therapeutics initiated with an Outperform at Wolfe Research
PremiumThe Fly
Akero Therapeutics initiated with an Outperform at Wolfe Research
3M ago
AKRO
MDGL
Madrigal Pharmaceuticals initiated with an Outperform at Wolfe Research
PremiumThe FlyMadrigal Pharmaceuticals initiated with an Outperform at Wolfe Research
3M ago
AKRO
MDGL
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
Premium
Press Releases
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
3M ago
AKRO
Madrigal, 89bio, Akero slip after Eli Lilly MASH data released
Premium
The Fly
Madrigal, 89bio, Akero slip after Eli Lilly MASH data released
4M ago
LLY
AKRO
Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI
PremiumThe Fly
Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI
4M ago
AKRO
MDGL
Akero Therapeutics price target lowered to $56 from $59 at Canaccord
PremiumThe Fly
Akero Therapeutics price target lowered to $56 from $59 at Canaccord
4M ago
AKRO
Akero Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Akero Therapeutics files automatic mixed securities shelf
4M ago
AKRO
Akero Therapeutics reports Q1 EPS (90c), consensus (95c)
PremiumThe Fly
Akero Therapeutics reports Q1 EPS (90c), consensus (95c)
4M ago
AKRO
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress ReleasesAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4M ago
AKRO
Akero Therapeutics appoints Gangloff as Chief Technology Officer
Premium
The Fly
Akero Therapeutics appoints Gangloff as Chief Technology Officer
5M ago
AKRO
Akero Therapeutics reinstated with a Neutral at BofA
Premium
The Fly
Akero Therapeutics reinstated with a Neutral at BofA
5M ago
AKRO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >